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Protein kinasesmay functionmore like variable rheo-
stats rather than two-state switches. However, we
lack approaches to properly analyze this aspect of
kinase-dependent regulation. To address this, we
develop a strategy in which a kinase inhibitor is iden-
tified using genetics-based screens, kinase muta-
tions that confer resistance are characterized, and
dose-dependent responses of isogenic drug-sensi-
tive and resistant cells to inhibitor treatments are
compared. This approach has the advantage that
function of wild-type kinase, rather than mutants, is
examined. To develop this approach, we focus on
Ark1, the fission yeast member of the conserved
Aurora kinase family. Applying this approach reveals
that proper chromosome compaction in fission yeast
needs high Ark1 activity, while other processes
depend on significantly lower activity levels. Our
strategy is general and can be used to examine the
functions of other molecular rheostats.
INTRODUCTION
Protein kinases are required for the regulation of a wide range of
cellular processes. An emerging theme, from the studies of
different kinases, is that these enzymes are not always acting
simply as ‘‘on’’ or ‘‘off’’ switches controlling a cellular process.
Rather they function as rheostats, with different activity levels
controlling specific and distinct phenotypic outcomes. For
example, analyses of Plo1, a Polo-like kinase in fission yeast,
suggest that processes required for cytokinesis (e.g., septum
formation) need higher Plo1 activity than other processes
required for cell division (e.g., spindle formation) (Ohkura et al.,
1995). In addition, the checkpoint kinase Rad3 is needed for
cell cycle arrest and recovery from DNA damage, and analysis
of mutants of Rad26, a regulatory subunit of Rad3, suggests
that different Rad3 activity levels control arrest and recovery
(Wolkow and Enoch, 2002). Further, studies of mutants of
Mps1, a conserved kinase that regulates cell division, indicate
that key steps in spindle pole body duplication are likely to262 Chemistry & Biology 20, 262–271, February 21, 2013 ª2013 Elsedepend on different kinase activity levels (Schutz and Winey,
1998). However, based on these studies, we are unable to prop-
erly establish that kinase activity levels alone control these
different phenotypes, as indirect effects, such as changes in
kinase localization, cannot be excluded.
Chemical inhibitor-based approaches can be used to control
kinase activity and analyze cellular function. However, as kinase
inhibitors can have limited or poorly characterized specificity,
their use as probes of mechanism can be restricted. A powerful
and widely used strategy to address this limitation is to use
the ‘‘bump-hole’’ approach, which involves using inhibitors
designed to specifically target mutant forms of the kinase of
interest but not thewild-type allele or any other kinase (Figure 1A;
Bishop et al., 2000). Recently, this approach has been used
to examine how different activity levels of cyclin-dependent
kinase (CDK) can define independent phases of the cell cycle
(Coudreuse and Nurse, 2010) and also to assess the activity
thresholds of human Plk1 kinase (Lera and Burkard, 2012).
However, drug-sensitive alleles of kinases can have reduced
activity when compared to the wild-type enzyme (Bishop et al.,
2000; Burkard et al., 2007; Koch and Hauf, 2010), and the
mutations in the kinase may not be entirely silent. For example,
cells expressing an engineered inhibitor-sensitive cdc2-allele
(cdc2-as) have reduced growth rates, temperature sensitivity,
and defects in cell cycle transitions, such as progression
through meiosis (Dischinger et al., 2008). In these cases, cells
may compensate for reductions in kinase activity levels and
complex regulatory networks may adapt, thereby complicating
interpretations.
Another alternate strategy, which allows analysis of wild-type
kinase function, is to examine dose-dependent phenotypes of
a kinase inhibitor in parallel experiments comparing isogenic
strains that are either inhibitor-sensitive or carry a mutation in
the inhibitor’s target that confers resistance but is otherwise
silent (Figure 1A). The off-target effects of the inhibitor would
be observed in both strains, while the on-target effects would
be observed in the drug-sensitive strain alone. To apply this
approach, we need to work with model organisms that
allow rapid selection and characterization of inhibitor resistance.
We also need chemical inhibitors that are active in the model
organism. As many diverse chemical scaffolds have been
described that inhibit kinases and structures of many kinase-
inhibitor complexes are available (Akritopoulou-Zanze and
Hajduk, 2009), small focused collections of compounds mayvier Ltd All rights reserved
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Figure 1. Human Aurora Kinase Inhibitors Are Not Active in Fission Yeast
(A) Schematic comparing two approaches that may be used to examine rheostat-like kinase function. (Left) Engineeredmutant kinases (as) but not wild-type (WT)
kinases are inhibited by inhibitor analogs that contain a sterically bulky substitution. (Right) WT kinases but not inhibitor-resistant kinases (R) are inhibited by
specific kinase inhibitors. Predicted kinase activity with or without inhibitors is shown as +++ (high), ++(intermediate), or - (low).
(B) Comparison of predicted hesperadin binding site residues in Xenopus laevis (Xenopus) Aurora B, human Aurora B (Human), Schizosaccharomyces pombe
Ark1 (SpArk1), Aspergillus fumigatus Ark1 (AfArk1), Cryptococcus neoformans Ark1 (CnArk1), Candida albicans Ipl1 (CaIpl1), and Saccharomyces cerevisiae Ipl1
(ScIpl1). For theCryptococcus neoformans homolog, we identify a proteinmost similar to SpArk1 using the Basic Local Alignment Search Tool and defined a gene
(GeneID: 3257153) as CnArk1.The residues in fungal kinases that are not conserved with human Aurora B are highlighted in pink.
(C–E) Kinase assay with recombinant fission yeast Ark1 (SpArk1) and human Aurora B (hAuroraB). The incorporation of the radioactive phosphate group was
visualized by autoradiography (32P), and protein loading was analyzed by staining with Coomassie Brilliant Blue (CBB). A representative data set is shown. The
grouping of images from different parts of the same gel is indicated by dividing lines.
(F) Exponentially growing culture (OD = 0.5) of WT (gray) and MDR-sup (black) cells were diluted 50 times in YE4S medium, treated with indicated compounds at
the indicated concentrations (mM), and incubated for 14 hr at 32C. Growth (%) is presented relative to DMSO-treated cells.
(G) Representative images of MDR-sup cells treated with 20 mM of the indicated compounds or DMSO are shown. Scale bars, 10 mm.
See also Figure S1.
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A Strategy to Study Rheostat-like Kinase Functionsbe sufficient to identify new probes. Screening strategies, such
as those that mimic synthetic lethal screens, can further increase
the efficiency in identifying useful chemical tools to examine how
dynamic cellular processes are regulated.Chemistry & Biology 20, 262Here, we develop and apply this approach to examine rheo-
stat-like kinase-dependent regulation using the fission yeast
(Schizosaccharomyces pombe), a useful genetically tractable
model organism, and focus on Aurora kinase, a conserved–271, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 263
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A Strategy to Study Rheostat-like Kinase Functionsregulator of cell division in eukaryotes. A small collection of
kinase inhibitor-like compounds and a synthetic lethal screen
was used to identify Arkin-1. We identified a single point muta-
tion in the fission yeast Aurora kinase (Ark1) that confers
resistance to Arkin-1 and use dose-dependent inhibition of
inhibitor-sensitive and resistant strains to analyze how different
levels of Aurora kinase activity control distinct processes
required for successful cell division.
RESULTS
Identifying a Chemical Probe for Fission Yeast Aurora
Kinase
To determine if available inhibitors of vertebrate Aurora kinases
can be used to probe the function of Ark1, the fission yeast
Aurora kinase (Petersen et al., 2001), we first examined the
X-ray structure of an inhibitor-kinase complex (Sessa et al.,
2005). We found that essentially all the residues in Xenopus
Aurora kinase that interact with the inhibitor, hesperadin, are
either identical or very similar to residues in fission yeast and
other fungi (Figure 1B). Only one amino acid in the inhibitor-
binding pocket is significantly altered (serine-229 in fission yeast
replaces alanine-233 in human Aurora kinase). Therefore, we
anticipated that available inhibitors of the human Aurora kinases,
e.g., hesperadin, ZM 447439, and VX-680, might inhibit the
fission yeast kinase.
To examine this, we expressed full-length fission yeast Ark1
and human Aurora B in bacteria and purified active kinase. As
anticipated, these compounds inhibited Ark1 in vitro, with poten-
cies that did not appear to be significantly reduced compared to
the inhibition of the human kinase (Figures 1C–1E). BI-2536,
a human Polo-like kinase 1 (PLK1) inhibitor (Le´na´rt et al., 2007;
Steegmaier et al., 2007), was used as a control and did not inhibit
Ark1 (Figures 1D and 1E). However, even though Ark1 is essen-
tial in vivo, cell growth of wild-type fission yeast was only partly
inhibited by these several selected chemical inhibitors, even at
relatively high concentrations (Figure 1F). As reduction in inhib-
itor efficacy can be due to multidrug resistance (MDR) mecha-
nisms in fission yeast, we used an MDR-sup fission yeast strain
that lacks four drug-efflux pumps and one transcription factor.
This strain is sensitive to a wide range of chemical inhibitors
(Kawashima et al., 2012). While hesperadin (20 mM) inhibited
growth of the MDR-sup cells, other inhibitors did not (Figure 1F).
As the concentration of hesperadin needed was significantly
higher than that needed to inhibit human cells, we needed to
validate that toxicity was due to Ark1 inhibition. Genetic knock-
down of the Aurora kinase complex in fission yeast show ‘‘cut
(cell untimely torn)’’ phenotypes (Petersen and Hagan, 2003).
However, hesperadin treatment did not show any cut pheno-
types (Figure 1G), suggesting that the major target responsible
for the toxicity of hesperadin in fission yeast is not likely to be
Aurora kinase. Together, these data indicate that the available
inhibitors of vertebrate Aurora kinases cannot be used as probes
in fission yeast.
Pathway-Targeted Chemical Screens Identified Arkin-1
As the available inhibitors were active against fission yeast Ark1
in vitro, it is possible that the lack of activity is due to partial cell or
nuclear permeability, and more permeable analogs of these264 Chemistry & Biology 20, 262–271, February 21, 2013 ª2013 Elseinhibitors could be found that are active in cells. However, it is
difficult to predict which available inhibitor’s analogs should be
generated and tested to identify a useful probe. Therefore, to
discover inhibitors active in cells, we designed a screen that
mimics conventional synthetic lethal genetic screens but,
instead of using mutations, selects compounds that are more
toxic to a mutant strain relative to a wild-type strain. We antici-
pated that ‘‘hits’’ from these screens would potentially target
proteins involved in the cellular pathway that carried the muta-
tion and are therefore likely to be more specific than inhibitors
identified using phenotype-based screens. Such chemical
genetic screens have thus far been carried out using budding
yeast (Nehil et al., 2007) but, as far as we are aware, not in
fission yeast. We focused on condensin, a multisubunit complex
needed for error-free cell division, whose function depends on
Aurora kinase (Nakazawa et al., 2011; Tada et al., 2011). We
introduced a mutation proximal to the Walker A motif in the
cut3 gene (cut3-KA), a subunit of the condensin complex, and
found that it results in ‘‘partial loss of function’’ (Figure S2
available online). We introduced this cut3 allele into the MDR-
sup strain and screened an in-house collection of 428 diverse
chemicals based on ‘‘privileged’’ chemical scaffolds that are
likely to target kinases and ATPases (Peters et al., 2006; Islam
et al., 2010). Analysis of MDR-sup and MDR-sup cut3-KA
strains treated with these compounds (6.7 mM) identified 102
compounds that reduced growth of MDR-sup cut3-KA cells
by >70%. Of these compounds, only one compound N-(4-
morpholinophenyl)-7-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-
2-amine showed >15% difference in the growth of MDR-sup
and MDR-sup cut3-KA cells (Figures 2A and 2B).
We next examined the effect of this hit on another stronger
loss of function condensin mutant (cut3-477) (Sutani et al.,
1999) and found that it was more sensitive than the cut3-KA
strain (Figure 2C). Importantly, this hit did not have enhanced
toxicity for a strain with a mutation in separase (cut1-22) (Funa-
biki et al., 1996), another essential mitotic enzyme (Figure 2C),
indicating that this compound selectively targets the chromo-
some condensation pathway. Unlike hesperadin and the other
available Aurora kinase inhibitors, cells treated with this pyrrolo-
pyrimidine revealed a cut phenotype, similar to that observed for
condensin or Aurora mutants (Figures 3B and 3C; Hirano et al.,
1986; Petersen and Hagan, 2003). Together, these data suggest
that this compound targets a protein required for proper chromo-
some condensation.
This pyrrolopyrimidine was structurally similar to INH-32,
an inhibitor developed for human Aurora kinase (Figure 2B)
that also potently inhibits the Flt3 kinase (Moriarty et al.,
2006). Therefore, we examined if our compound targeted Ark1
in vitro and in vivo. We observed dose-dependent inhibition of
the phosphorylation of histone H3 by recombinant Ark1 as
well as human Aurora B protein (Figure 2D). Next, we examined
Ark1 inhibition in cells. As Ark1 activity is mainly restricted to
mitosis, we accumulated mitotic cells by inhibiting the protea-
some using Velcade and examined the level of histone H3
phosphorylation at Serine 10. We observed a dose-dependent
suppression of this phosphorylation (Figures 2E and 3D). In
contrast, other human Aurora kinase inhibitors, such as hesper-
adin, ZM 447439, and VX-680, were not or only weakly active in
this assay (Figure 2E). Together, these data indicate that Ark1 isvier Ltd All rights reserved
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Figure 2. Chemical Synthetic Lethal Screen
Using the MDR-sup Fission Yeast Identifies
an Ark1 Inhibitor, Arkin-1
(A) Analysis of growth of cells treated with com-
pounds from a 428-member chemical library
(6.7 mM). Scatter plot shows the growth of
the MDR-sup cut3-KA strain (x axis) and the
difference in growth between MDR-sup (control)
and MDR-sup cut3-KA strain (y axis). Growth
was normalized to DMSO-treated cells. Arkin-1 is
indicated.
(B) Chemical structures of Arkin-1 and INH-32 are
shown.
(C) Exponentially growing culture (OD = 0.5) of
MDR-sup (control: black circle), MDR-sup cut3-
KA (cut3-KA: light gray circle), MDR-sup cut1-22
(cut1-22: triangle), and MDR-sup cut3-477 (cut3-
477: dark gray circle) cells were diluted 50 times
in YE4S medium and treated with Arkin-1 and
incubated for 17 hr at 29C. Growth (%) is pre-
sented relative to DMSO-treated cells.
(D) Kinase assay with recombinant fission yeast
Ark1 and human Aurora kinase. The incorporation
of the radioactive phosphate group was visualized
by autoradiography (32P), and protein loading was
analyzed by staining with CBB. A representative
data set is shown.
(E) MDR-sup cells were blocked at S-phase by HU to prepare the S-Phase extract (S). To prepare the M-phase extract (M), cells were released from S-phase,
incubated for 30 min, and treated with Velcade (40 mM) and indicated Aurora inhibitors for 60 min. The level of histone H3-pS10 was estimated by immunoblot.
Tubulin is the loading control.
See also Figure S2.
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Ark1 inhibitor-1).
Isolating Arkin-1-Resistant Mutants
To determine if Ark1 is themajor physiological target of Arkin-1 in
fission yeast, we isolated mutants that are resistant to Arkin-1
using an MDR-sup cut3-KA strain. We chemically mutagenized
cells and isolated nine resistant clones, which could grow on
plates containing Arkin-1 (7.5 mM). As these clones are sensitive
to brefeldin A (Figures 3A and S2C) and cycloheximide (Fig-
ure S2C), we concluded that these mutations are unlikely to be
in MDR genes. We sequenced the ark1 gene in each drug-resis-
tant clone and found that all nine clones had the same residue
mutated, Gly172 (six clones: G172D; two clones: G172S; and
one clone: G172C). To confirm that this point mutation in Ark1
is sufficient to confer drug resistance, we constructed a strain
in which endogenous ark1+ gene was replaced by the ark1-
G172D mutant. Similar to the isolated resistant mutants, the
ark1-GD mutant was almost completely resistant to Arkin-1
over a range of Arkin-1 concentrations (Figure S3A). Ark1-GD
was likely functional, as growth of ark1-GD mutant strains was
comparable to that of wild-type cells and the localization of
Ark1-GD was similar to that of Ark1 (Figures S3A and S3B). We
found that abnormal nuclear division as well as the reduction
of histone H3 phosphorylation at Serine 10 in Arkin-1-treated
cells was almost completely suppressed by the ark1-GD muta-
tion (Figures 3B–3D). It is noteworthy that corresponding muta-
tions at this glycine residue in human Aurora kinase have been
found to confer resistance to other Aurora inhibitors (hesperadin,
ZM 447439, and VX-680) (Balzano et al., 2011; Girdler et al.,
2008; Scutt et al., 2009), and it is likely that the Arkin-1, like theseChemistry & Biology 20, 262other Aurora inhibitors, targets the nucleotide-binding pocket.
Together these data indicate that the primary physiological
target of Arkin-1 in fission yeast is Ark1, and Arkin-1 is a specific
chemical inhibitor of fungal Aurora kinase.
Examining the Roles of Different Ark1 Kinase Activity
Levels in Mitosis
Aurora kinase activity gradually increases from prophase to
metaphase and then reduces after chromosomes start segre-
gating (Tan and Kapoor, 2011). Nevertheless, Aurora kinase is
essential for processes that are needed from the start of mitosis
(e.g., regulation of kinetochore-microtubule attachments) and
those that may be completed later in mitosis (e.g., chromosome
condensation). Therefore, Aurora-dependent regulation of these
processes may depend on different levels of kinase activity.
Recently, a study using several INCENP mutants in chicken
DT40 cells has suggested that higher levels of Aurora B kinase
activity are required for completing cytokinesis (Xu et al.,
2010). However, as ark1 mutants show cut phenotypes, fission
yeast Ark1 is not required for completing cytokinesis. Moreover,
requirement of different Aurora kinase activity levels for kineto-
chore-microtubule attachments or chromosome condensation
has not been addressed. To examine Ark1 kinase activity-
dependent regulation of chromosome segregation, we used
Arkin-1 and parallel analyses of dose-dependent phenotypes
in inhibitor-sensitive and resistance cells. As Arkin-1 did not
work in the wild-type background, we used the MDR-sup strain
for all the experiments (Figure S2D).
We first analyzed the level of phosphorylation of a key
substrate (Histone H3) over a range of Arkin-1 concentrations.
Substrate phosphorylation was reduced by 40% at 2 mM–271, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 265
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Figure 3. Identification of an Arkin-1-Resis-
tant Mutant
(A) MDR-sup cut3-KA cells (host) and Arkin-1-
resistant cells (Arkin-1r) were streaked on YE4S
plate or YE4S plate containing Arkin-1 (7.5 mM) or
brefeldin A (2 mM) and incubated at 29C.
(B and C) The frequency of abnormal chromosome
segregation was examined in MDR-sup cut3-KA
cells (ark1+), Arkin-1-resistant clone (MDR-sup
cut3-KA background) (Arkin-1r), and MDR-sup
cut3-KA ark1-GD (ark1-GD) cells after 5 mM Arkin-
1 (or DMSO) treatment in asynchronous culture
(2.5 hr at 32C [n > 250]). Representative images
are shown. Scale bars, 10 mm.
(D) MDR-sup cut3-KA cells, with or without ark1-
GD mutation, were blocked at S-phase by HU to
prepare the S-Phase extract (S). To prepare theM-
phase extract (M), these strains were released
from S-phase, incubated for 30 min, and treated
with 10 mM Velcade and Arkin-1 for 60 min. The
level of histone H3-pS10 was estimated by
immunoblot. Tubulin is the loading control.
See also Figure S3.
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A Strategy to Study Rheostat-like Kinase FunctionsArkin-1 and90% at 5 mMor 7.5 mMArkin-1 (Figure S4). We also
analyzed the localization of Ark1 in Arkin-1-treated cells and
found that the centromeric localization of Ark1 was intact in
7.5 mM Arkin-1-treated cells (Figure S3C). We next examined
Ark1’s spindle assembly checkpoint (SAC) function by using no-
codazole to induce microtubule depolymerization and activate
the SAC and then treating with Arkin-1. In addition, we analyzed
kinetochore localization of Mad2 at kinetochores, an indicator
of SAC activation. To examine Ark1’s function in correcting
errors in kinetochore-microtubule attachments, we analyzed
the frequency of improper attachments, including syntelic and
merotelic attachments, by tracking chromosome II segregation
using cen2-green fluorescent protein (GFP) (Hauf et al., 2007).
To examine Ark1’s function in chromosome condensation, we
measured the frequency of cells that have reduced chromosome
compaction compared to controls but have normally separated
cen2-GFP signals during anaphase. Our measure of chromo-
some condensation defects is likely to be an underestimate, as
we do not include cells with improper chromosome attachments.
Treatment with high doses of Arkin-1 (7.5 mM) resulted in
SAC defects with loss of Mad2 localization, defects in correcting
errors in kinetochore-microtubule attachments, and improper
chromosome condensation (Figures 4A–4D). All these defects
were suppressed in ark1-GD strain (Figures 4A–4D), suggesting
that observed phenotypes depend on Ark1’s kinase activity. Low
doses of Arkin-1 (2 mM) treatment resulted in obvious defects of
chromosome condensation (46%± 4%, two independent exper-
iments). Interestingly, errors in kinetochore-microtubule attach-
ments were very low (3.1%), and SAC arrest/Mad2 localization
was unaltered under these conditions (Figures 4A–4D). An inter-
mediate dose of Arkin-1 (5 mM) treatment shows partial defects
in SAC arrest/Mad2 localization and error correction and severe
defects in chromosome condensation (Figure 4A–4D). Together,
these data suggest that proper chromosome condensation
requires higher levels of Ark1 kinase activity than that needed
for the spindle assembly checkpoint or to establish proper kinet-
ochore-microtubule attachments.266 Chemistry & Biology 20, 262–271, February 21, 2013 ª2013 ElseTo further characterize defects of chromosome compaction
induced by low doses of Arkin-1, we quantitatively analyzed
the separation of centromeres (indicated by imr3-tdTomato;
Sakuno et al., 2009) or chromosome arm regions (indicated by
arm-GFP, centromeric side of the ribosomal DNA [rDNA] locus;
Tada et al., 2011) of chromosome III (ch3) during anaphase. In
addition, as Aurora kinase is required for efficient separation of
nucleoli or rDNA in budding yeast (Sullivan et al., 2004), we
also analyzed the separation of the nucleolus, indicated by
cyan fluorescent protein (CFP)-fused Gar1 (Tada et al., 2011).
Consistent with the results that attachment defects of centro-
mere II were only rarely observed at low doses of Arkin-1 (Figures
4C and 4D), separation of ch3-centromeres in Arkin-1-treated
cells was comparable to DMSO-treated controls (Figure 5A). In
contrast, separation of ch3-arm and nucleolus was significantly
less efficient at low doses of Arkin-1 (Figures 5B and 5D). These
defects were suppressed in ark1-GD cells, even at the highest
concentration (7.5 mM) of Arkin-1, confirming specificity (Figures
S5A and S5B).
Ark1 phosphorylates the amino-terminal fragment of Cnd2
(homolog of human Barren), and the phosphomimetic mutant
cnd2-3E suppresses the growth defect by Ark1 inhibition (Naka-
zawa et al., 2011; Tada et al., 2011). Therefore, we examined if
reduction of Cnd2 phosphorylation is the major reason under-
lying the observed chromosome compaction defects. If true,
low dose of Arkin-1 treatment should not enhance chromosome
compaction defects in the cnd2-3E mutant background.
However, Arkin-1 treatment significantly reduced separation
of chromosome arms and nucleoli (Figures 5E, 5F, S5E, and
S5F), suggesting that Ark1-dependent phosphorylation of
factors other than Cnd2 is also important for proper chromo-
some compaction.
Mitotic phosphorylation of substrates depends on a balance
between kinase and phosphatase activity (Bollen et al., 2009).
Protein phosphatase 1 (PP1) opposes Aurora-dependent regu-
lation of the SAC (in fission yeast; Meadows et al., 2011; Vanoos-
thuyse and Hardwick, 2009) and chromosome-microtubulevier Ltd All rights reserved
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Figure 4. Examining the Contributions of
the Kinase Activity of Ark1 during Mitosis
Duration of Arkin-1 treatment is 1 hr for all the
experiments.
(A and B) Synchronized MDR-sup plo1-mYFP
mad2-mcherry cells, with or without ark1-GD
mutation, was treated with nocodazole (A) or
nocodazole/Velcade (B) for 45 min, and then the
indicated concentrations of Arkin-1 were added.
Percentage of cells with strong dot-like signals of
Plo1-mYFP (gray) or Mad2-mcherry (black) were
analyzed (n > 200). The Plo1 signals at spindle pole
bodies, which depend on CDK activity, are an
indicator of (pro)metaphase cells.
(C) Synchronized MDR-sup mcherry-atb2 cen2-
GFP cells, with or without ark1-GD mutation,
were treated with the indicated concentrations
of Arkin-1. The percentage of erroneous kineto-
chore-microtubule attachments in anaphase cells
were analyzed (n > 100). Representative images
are shown. Scale bars, 2 mm.
(D) Synchronized MDR-sup plo1-mYFP cen2-GFP
cells were treated with the indicated concen-
trations of Arkin-1. The percentage of each
phenotype (white: normal; red: condensation
defects; blue: missegregation of centromeres) in
Plo1-negative anaphase cells were analyzed
(n > 150). Representative images are shown. Scale
bars, 2 mm.
See also Figure S4.
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A Strategy to Study Rheostat-like Kinase Functionsattachment (in human cells; Liu et al., 2010). Consistent with
these reports, deletion of Dis2, the kinetochore-localized isoform
of PP1 (Alvarez-Tabare´s et al., 2007), suppressed delocalization
of Mad2 from kinetochore and error correction defects in Arkin-
1-treated MDR-sup fission yeast cells (Figures S5C and S5D).
Because the phosphatases counteracting Aurora-dependent
chromosome compaction are unknown, we examined if Dis2 is
involved in this regulation. Strikingly, deletion of Dis2 suppressed
the defects of ch3-arm and nucleolus separation in cells treated
with low doses of Arkin-1 (Figures 5C and 5D). These data
suggest that PP1 counteracts Aurora-dependent chromosome
compaction in fission yeast.
DISCUSSION
In this study, we present a strategy to investigate how distinct
cellular phenotypes can be regulated via differences in protein
kinase activity levels. Our strategy involves the identification of
a cell-permeable kinase inhibitor, selection and characterization
of mutations in the inhibitor’s target, and analysis of dose-
dependent phenotypes in inhibitor-sensitive or resistant isogenic
cells (Figure 1A). This strategy has advantages over other
chemical genetic strategies, as concerns relating to inhibitor
specificity or compensation/adaptation in cells with partially
impaired kinase can be addressed. In the case of Ark1, the
bump-hole approach has begun to be developed and ‘‘analog
sensitive’’ (ark1-as2 or ark1-as3) alleles have been described
(Koch and Hauf, 2010). The strains expressing these ark1 allelesChemistry & Biology 20, 262reveal some chromosome segregation errors, even in the
absence of inhibitors (Koch and Hauf, 2010), and generating
completely silent alleles appears to be challenging. Therefore,
the effective use of this powerful strategy remains restricted.
Our approach examining the wild-type Ark1 provides a useful
alternate and, at this stage, is likely to allow for stronger interpre-
tations of experiments analyzing the rheostat-like functions of
Ark1 during cell division.
While potentially general, our strategy depends on identifying
resistance-conferring mutations in the inhibitor’s target that do
not disrupt function. While it is extremely difficult to establish
that the mutant has no phenotype at all (Yun et al., 2008), it is
easier to determine if there is a phenotype in the cellular process
we wish to examine. Moreover, as these mutations interfere with
drug binding rather than ATP-binding, a function essential for
kinase activity, it is more likely that mutations can be identified
that confer drug resistance but preserve overall function. Con-
sistent with this assumption, we identified Arkin-1 resistance,
conferring mutations that did not significantly reduce growth
and had a less than 5% defect in chromosome segregation.
Examining other mutations, such as ark1 (G172L) that, based
on studies with other inhibitors, (Scutt et al., 2009) should also
confer Arkin-1 resistance,may yield strains that have evenmilder
phenotypes.
The successful application of our approach also depends
on finding chemical inhibitors that are active in cells. One
strategy to identify inhibitors for a kinase of interest is to use
structural data and analyze the conservation of residues in the–271, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 267
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Figure 5. Proper Separation of Chromosome Arms and Nucleoli Needs High Levels of Ark1 Activity
Synchronized MDR-sup cells (A and B: wild-type; C and D: dis2D; and E and F: cnd2-3E) were treated with 2 mM Arkin-1 (or DMSO) for 1 hr at 32C. Tubulin,
imr3-tdTomato (ch3-centromere) or arm-GFP (ch3-arm), Gar1-CFP (nucleoli), and DNA were imaged.
(A–C and E) The distance of imr3-tdTomato (ch3-centromere) or arm-GFP (ch3-arm) dots and spindle length in anaphase cells were analyzed (n > 48). In the
graphs, each circle indicates one anaphase cell treated with 2 mM Arkin-1 (red) or DMSO (black). Representative images are shown. Scale bars, 2 mm.
(D and F) Frequency of unseparated nucleolus indicated by Gar1-CFP in DMSO or 2 mMArkin-1-treated cells was analyzed. As nucleoli were not yet separated in
50% early anaphase DMSO-treated cells (spindle length < 7 mm), late anaphase cells (7 mm < spindle length < 11 mm) were analyzed (n > 33).
See also Figure S5.
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A Strategy to Study Rheostat-like Kinase Functionsdrug-binding pockets to determine if an available probe may be
active. However, we find that available Aurora kinase inhibitors
are inactive in fission yeast cells, despite the drug-binding
pockets of the fission yeast and human Aurora kinases being
very similar. For other highly conserved kinases, such as Polo-
like kinase, analysis of drug-binding sites of BI2536, a specific
inhibitor of human PLK1, reveals even greater divergence
between the fungal and human kinase (Figure S1A). Consistent
with these analyses, we found that fission yeast strains were
not sensitive to extremely high concentrations of BI-2536
(>10 mM) compared to active dose for human cells (10 nM) (Fig-
ure S1B). Together, these data suggest that available inhibitors
that target vertebrate kinases may not work in fission yeast,
most likely due to differences in cell permeability or divergence
in the drug-binding pockets. To address this limitation, the268 Chemistry & Biology 20, 262–271, February 21, 2013 ª2013 Elsedeletion of additional genes to increase cell permeability may
be considered but is not likely to be very practical, due to
reduced strain viability and restrictions in additional genetic
manipulations of the MDR-sup strain we have recently devel-
oped. We believe that, while the available inhibitors may not
work, their analogs may well be effective and can be efficiently
identified using ‘‘chemical synthetic lethal’’ screens, as used
here. This screening strategy has the advantage that it is likely
to identify compounds that are selective for the target pathway,
addressing at an early stage of the discovery process a key
limitation of chemical inhibitors. Furthermore, we can increase
the fidelity of this selection by testing drug sensitivity of
another mutant in the target pathway (e.g., cut3-477) and by
the lack of increased activity against an unrelated mutant (e.g.,
cut1-22) (Figure 2C).vier Ltd All rights reserved
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and resistant strains revealed that proper chromosome compac-
tion, which is essential for efficient separation of chromosome
arms and nucleoli during anaphase, requires higher levels of
Ark1 kinase activity than that needed either for checkpoint
signaling or for establishing proper kinetochore-microtubule
attachments. The SAC and the error correction mechanisms
must be active early during mitosis (prophase-prometaphase),
while proper chromosome compaction could be achieved by
late mitosis and needs to be completed prior to anaphase
(metaphase-anaphase). Therefore, the dependence of these
processes on different levels of kinase activity suggests that
the changes in Aurora kinase activity during mitosis can help to
establish temporal order during cell division.
Our observations can be explained by a model in which
phosphorylation of substrates located proximal to the site where
the kinase is localized is more efficient than the modification
of substrates that are more distal (Fuller et al., 2008; Wang
et al., 2011). Ark1 substrates regulating Mad2 recruitment or
kinetochore-microtubule attachments are likely to be enriched
at the kinetochore, which is proximal to the centromere, where
most Ark1 accumulates prior to anaphase. In contrast, Ark1
substrates regulating chromosome compaction (e.g., conden-
sins) are likely to localize all along chromosome arms, which
can extend microns away from the centromere and thus are
displaced from the majority of Ark1. Therefore, regulation of
kinetochore function may require lower levels of kinase activity
than that needed for substrates distributed along the entire
chromosome. Alternative models, such as differences between
chromosome and kinetochore substrate affinities or even local
substrate concentrations, may also explain our observations.
Additional studies will have to be designed to further examine
these possibilities. How chromosomes are properly compacted
for cell division remains poorly understood. Our data indicate
that phosphoregulation of the condensin subunit Cnd2 alone
does not account for the observed phenotype, and at least one
more unknown factor must be regulated by Ark1 and PP1 to
achieve proper chromosome compaction. Interestingly, con-
densin-independent chromosome compaction regulated by
PP1 has been suggested by a study examining cell division in
chicken DT40 cells (Vagnarelli et al., 2006), and this may be
relevant to the unknown factor. Finding this factor, which is likely
to be conserved among eukaryotes, is an important goal, and
fission yeast may be well-suited for these studies.
The level of substrate phosphorylation depends on a balance
in kinase and phosphatase activity. In humans and in fission
yeast cells, PP1 targets to multiple sites, including nucleolus,
kinetochores, and chromatin (Alvarez-Tabare´s et al., 2007;
Trinkle-Mulcahy et al., 2006), suggesting that PP1 dynamically
regulates multiple cellular events. Our data indicate that PP1
counteracts Aurora-dependent regulation of chromosome
condensation. Understanding the precise contribution of phos-
phatases to rheostat-like regulation is difficult, due to the fact
that diversity in phosphatase function is achieved by distinct
regulatory subunits in different holoenzyme complexes that
share a common catalytic subunit. Developing good compounds
that selectively inhibit a particular phosphatase holoenzyme
complex has been challenging, as protein-protein interactions
need to be disrupted, something that is not readily achieved byChemistry & Biology 20, 262low molecular weight cell permeable small molecules (Arkin
and Wells, 2004). Chemical synthetic screens for phosphatase
inhibitors may be successful, particularly if the compound
libraries tested are large, diverse, and include scaffolds with
features that can increase the likelihood that protein-protein
interactions are inhibited (Morelli et al., 2011). These chemical
probes, along with characterized resistance-conferring mutant
forms of the phosphatase, will be useful for examining how
kinases and phosphatases quantitatively communicate and
regulate cell division dynamics.
Our approach could be applied to examine the rheostat-like
regulation of dynamic and essential cellular processes by
other kinases, such as Rad3 or Mps1. In principle, our strategy
can also be applied to other regulatory enzymes, such as
histone-modifying enzymes, for which several different
chemical inhibitors have recently been reported (Cole, 2008),
and therefore, identifying probes active in fission yeast should
be feasible. In addition to serving as probes of cellular mecha-
nisms, it is possible that the chemical inhibitors we identify
and validate will provide starting points for developing new
antifungal drugs.
SIGNIFICANCE
Studies of different kinases suggest that these enzymes are
not acting simply as ‘‘on’’ or ‘‘off’’ switches controlling a
cellular process. Rather they function as variable rheostats,
with different activity levels controlling specific and distinct
phenotypic outcomes. We report a proof-of-concept study
developing a robust chemical biology strategy to analyze
rheostat-like protein kinase-dependent regulation. This
approach involves the use of genetic screens to identify
a chemical probe for a kinase of interest, characterization
of mutations in the kinase that confer resistance, and
then comparisons between dose-dependent responses
of isogenic drug-sensitive and resistant cells to inhibitor
treatment. To develop the approach, we focused on Aurora
kinase, a conserved regulator of cell division in eukaryotes.
We used a synthetic lethal screen to identify Arkin-1,
a specific inhibitor of fission yeast Aurora kinase (Ark1),
and characterized a resistance-conferring point mutation
in Ark1. Parallel experiments analyzing the responses of
drug-sensitive and resistant cells to controlled amounts of
Arkin-1 revealed that efficient separation of chromosome
arms and nucleoli, which depend on proper chromosome
compaction, needs high levels of Ark1 activity. In contrast,
regulation of checkpoint signaling and chromosome-micro-
tubule attachments needs significantly less kinase activity.
Further chemical genetic experiments using low doses of
Arkin-1 suggested that Ark1-dependent phosphoregulation
of an unknown factor, other than the condensin subunit
Cnd2, and the phosphatase protein phosphatase 1 are
needed to achieve proper chromosome compaction. Our
approach could be applied to examine the rheostat-like
regulation of dynamic and essential cellular processes by
other kinases. In addition to serving as probes of cellular
mechanisms, it is possible that the chemical inhibitors
we identify and validate will provide starting points for
developing new antifungal drugs.–271, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 269
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Schizosaccharomyces pombe Strains
All strains used are listed in Table S1. Standard growth conditions and
methods were used (Moreno et al., 1991). All experiments were performed in
yeast extract (YE) medium containing adenine, leucine, uridine, and histidine.
The PCR-based gene targeting (Ba¨hler et al., 1998) was used to construct
gene disruptants and fluorescent protein–tagged strains with selection marker
gene cassettes. The MDR-sup strain is an engineered drug-sensitive fission
yeast, in which five genes were deleted (pap1D bfr1D pmd1D mfs1D caf5D)
(Kawashima et al., 2012).
Immunoblotting
Total protein was extracted using glass beads (Moreno et al., 1991), separated
by SDS-PAGE, and transferred to membrane filters. For primary antibodies,
antiphospho-Histone H3 (Ser10) (1:2,000, Millipore) and TAT-1 (1:2,000;
a gift from K. Gull; Woods et al., 1989) were used.
Chemical Synthetic Lethal Screen
AI61 and AI82 strains (Table S1) were used for the chemical genetic screen.
Logarithmically growing cells (optical density [OD] = 0.5) were diluted ten
times, mixed with compounds (6.7 mM) and YE medium (total volume: 50 ml
per well), and incubated for 12 hr at 29C. Multidrop Combi (Thermo Scientific)
was used to dispense the cells into wells of the 384-plate (Greiner clear flat
bottom PS plate). The growth was measured by microtiter plate reader
(Perkin-Elmer EnVision, 590 nm filter). For calculation of growth ratio, OD
values of each well were divided by that of control well incubated with DMSO.
Isolation of Arkin-1-Resistant Mutants
AI164 strain (Table S1) wasmutagenized by treatment with 1-methyl-3-nitro-1-
nitrosoguanidine (NTG) (25 mg/ml, 75% viability compared to no NTG condi-
tion) in Tris maleic acid buffer (50 mM Tris, 50 mM maleic acid, 7.5 mM
(NH4)2SO4, 0.4 mM MgSO4$7H2O, pH 6.0) for 30 min and incubated in YE
medium for >3 hr, spread onto plates containing 7.5 mM Arkin-1. Nine Arkin-
1-resistant mutants were isolated from 106 cells.
Synchronization of MDR-sup Cells
MDR-sup cells were blocked at S-phase using hydroxyurea (HU) and released
from S phase by washing out HU at 32C. Nocodazole (15 mM) or Velcade
(40 mM) was added 30 min after release to activate the spindle checkpoint
with unattached kinetochores or to prevent metaphase-anaphase transition,
respectively.
Microscopy
Cells were fixed using methanol, stained with DAPI, imaged by a microscope
(Axioplan 2; Carl Zeiss), and processed with MetaMorph software (Molecular
Devices), as described previously (Kawashima et al., 2012).
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